Lupus nephritis give me breif summary

Reading File

Finding Sources

Reading File

I now have sufficient material from the textbooks to provide a comprehensive brief summary. Let me compile this.

Lupus Nephritis — Brief Summary

Definition & Epidemiology

Lupus nephritis (LN) is renal involvement in systemic lupus erythematosus (SLE), affecting all parenchymal compartments (glomeruli, vessels, tubules, and interstitium). It is the leading cause of morbidity and mortality in lupus. Clinically significant kidney disease is seen in ~30% of SLE patients. LN is most common in Black females aged 15–45, and carries particularly high prevalence in Asian populations, where it is the leading cause of secondary glomerular disease. — Henry's Clinical Diagnosis and Management by Laboratory Methods

Pathogenesis

Immune complex deposition driven by autoantibodies (especially anti-dsDNA, anti-Sm, antiphospholipid antibodies) activates complement and triggers glomerular inflammation. Genetic polymorphisms (>50 identified) involve defective immune clearance of apoptotic debris, altered innate/adaptive immunity, and kidney-specific effector mechanisms. — Brenner and Rector's The Kidney

Clinical Features

Microscopic hematuria, red cell casts
Proteinuria (mild to nephrotic-range)
Nephrotic syndrome
Renal insufficiency / rising creatinine
Tubular defects

ISN/RPS Classification (6 Classes)

Class	Description
I	Minimal mesangial LN — normocellular glomeruli, mesangial IgG deposits only on IF
II	Mesangial proliferative LN
III	Focal LN (<50% glomeruli affected)
IV	Diffuse LN (≥50% glomeruli; most severe) — wire-loop lesions, endocapillary hypercellularity, subendothelial deposits
V	Membranous LN — subepithelial deposits
VI	Advanced sclerosing LN

Class IV is the most severe and features characteristic wire-loop deposits of subendothelial immune complexes with full-house immunofluorescence (IgG, IgA, IgM, C3, C1q). — Henry's Clinical Diagnosis and Management

Diagnosis

Urinalysis: hematuria, red cell casts, proteinuria
Serology: ANA, anti-dsDNA (elevated), complement low (C3, C4)
Kidney biopsy: gold standard for classification and guiding therapy
ACR criteria: ≥4 of 11 criteria gives 96% sensitivity/specificity for SLE
SLICC criteria: biopsy-proven LN alone (with ANA or anti-dsDNA) can satisfy diagnosis

Treatment

Induction (active/proliferative disease — Class III/IV):

Corticosteroids + Mycophenolate mofetil (MMF) (preferred) OR
Corticosteroids + IV Cyclophosphamide (IVC)
Biologic option: Rituximab (used in refractory cases, though evidence is mixed)
Belimumab (voclosporin combination increasingly used per newer guidelines)

Maintenance:

MMF or azathioprine + low-dose steroids
Hydroxychloroquine — given to all SLE/LN patients; reduces flares

Adjuncts:

RAS blockade (for proteinuria/BP) — held in pregnancy
Plasma exchange: not routinely beneficial in LN trials — Brenner and Rector's The Kidney

Pregnancy Considerations

LN flares occur in ~30% during pregnancy and ~15% postpartum
Hydroxychloroquine continued throughout pregnancy
MMF and cyclophosphamide are teratogenic — switch to azathioprine before conception
Tacrolimus is an alternative during pregnancy
Low-dose aspirin for preeclampsia prophylaxis
Poor prognostic factors: creatinine >0.9 mg/dL, proteinuria >0.5 g/24h, antiphospholipid syndrome, hypertension — Comprehensive Clinical Nephrology & National Kidney Foundation Primer

Prognosis

Poor outcomes associated with: high baseline creatinine, significant chronic damage on biopsy, crescents, vascular/endothelial lesions, anti-Sm positivity, and presentation after age 50. Class IV carries the greatest risk of progression to end-stage kidney disease (ESKD).

Chronic GN summary easy for rounds in medicine

Finding Sources

Reading File

Finding Sources

Reading File

Your credits are exhausted. Your daily credits reset tomorrow, or you can purchase a top-up for more.

This is a shared conversation. Sign in to Orris to start your own chat.